

PTC THERAPEUTICS, INC.  
Form 4  
June 10, 2015

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Peltz Stuart Walter

2. Issuer Name and Ticker or Trading Symbol  
PTC THERAPEUTICS, INC.  
[PTCT]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
06/08/2015

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chief Executive Officer

C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT  
(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

SOUTH PLAINFIELD, NJ 07080

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/08/2015		M <sup>(1)</sup>		60,306	A	\$ 10.85
Common Stock	06/08/2015		M <sup>(1)</sup>		17,170	A	\$ 10.85
Common Stock	06/08/2015		S <sup>(1)</sup>		11,825	D	\$ 53.81 <u>(2)</u>
Common Stock	06/08/2015		S <sup>(1)</sup>		36,075	D	\$ 54.64 <u>(3)</u>

Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

Common Stock	06/08/2015	<u>S</u> <sup>(1)</sup>	22,300	D	\$ <u>(4)</u>	7,276	D
Common Stock	06/08/2015	<u>S</u> <sup>(1)</sup>	3,500	D	\$ 56.4 <u>(5)</u>	3,776	D
Common Stock	06/09/2015	<u>M</u> <sup>(1)</sup>	26,300	A	\$ 10.85	30,076	D
Common Stock	06/09/2015	<u>S</u> <sup>(1)</sup>	12,500	D	\$ <u>(6)</u>	17,576	D
Common Stock	06/09/2015	<u>S</u> <sup>(1)</sup>	13,400	D	\$ <u>(7)</u>	4,176	D
Common Stock	06/09/2015	<u>S</u> <sup>(1)</sup>	400	D	\$ <u>(8)</u>	3,776	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 10.85	06/08/2015		<u>M</u> <sup>(1)</sup>	60,306	<u>(9)</u>	05/15/2023	Common Stock	60,306
Stock Option (Right to Buy)	\$ 10.85	06/08/2015		<u>M</u> <sup>(1)</sup>	17,170	<u>(10)</u>	05/15/2023	Common Stock	17,170
Stock Option (Right to Buy)	\$ 10.85	06/09/2015		<u>M</u> <sup>(1)</sup>	26,300	<u>(10)</u>	05/15/2023	Common Stock	26,300

Buy)						
Stock Option (Right to Buy)	\$ 27.05		<u>(11)</u>	01/27/2024	Common Stock	200,000
Stock Option (Right to Buy)	\$ 51		<u>(12)</u>	01/01/2025	Common Stock	300,000
Stock Option (Right to Buy)	\$ 218.4		<u>(13)</u>	01/10/2022	Common Stock	416
Stock Option (Right to Buy)	\$ 490.8		<u>(14)</u>	04/27/2021	Common Stock	541
Stock Option (Right to Buy)	\$ 1,149.6		<u>(14)</u>	02/02/2020	Common Stock	583
Stock Option (Right to Buy)	\$ 451.2		<u>(14)</u>	05/15/2019	Common Stock	583
Stock Option (Right to Buy)	\$ 735.6		<u>(14)</u>	04/01/2018	Common Stock	293
Stock Option (Right to Buy)	\$ 735.6		<u>(14)</u>	01/25/2018	Common Stock	708
Stock Option (Right to Buy)	\$ 626.4		<u>(14)</u>	04/18/2017	Common Stock	322
Stock Option (Right to Buy)	\$ 392.4		<u>(14)</u>	03/01/2016	Common Stock	136

## Reporting Owners

Reporting Owner Name / Address

Relationships

Reporting Owners

Director    10% Owner    Officer    Other

Peltz Stuart Walter  
C/O PTC THERAPEUTICS, INC.  
100 CORPORATE COURT  
SOUTH PLAINFIELD, NJ 07080

X

Chief Executive Officer

## Signatures

/s/ Colleen Diver Johnson,  
attorney-in-fact

06/10/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person for the primary purposes of diversification.
- (2) This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$53.26 to \$54.25 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- (3) This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$54.26 to \$55.18 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- (4) This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$55.26 to \$56.12 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- (5) This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$56.26 to \$56.59 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- (6) This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$52.23 to \$53.21 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- (7) This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$53.23 to \$54.22 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- (8) This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$54.25 to \$54.30 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- (9) This option was granted on May 15, 2013 and vests over four years, with 25% of the shares underlying the option vested on December 31, 2013 and an additional 2.083% of the original number of shares underlying the option vesting monthly thereafter beginning on January 31, 2014.
- (10) This option was granted on May 15, 2013 and vests over four years, with 25% of the shares underlying the option vested on May 15, 2014 and an additional 2.083% of the original number of shares underlying the option vesting monthly thereafter beginning on June 15, 2014.
- (11) This option was granted on January 28, 2014 and vests over four years, with 25% of the shares underlying the option vested on January 1, 2015 and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2015.
- (12) This option was granted on January 2, 2015 and vests over four years, with 25% of the shares underlying the option vesting on January 1, 2016 and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2016.
- (13)

## Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

This option was granted on January 10, 2012 and vests over four years, with 25% of the shares underlying the option vested on January 1, 2013 and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2013.

**(14)** Currently exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.